Genex Pharmaceutical GENX · USD

Market value

$642

Last close × shares

Volume

200k

Shares, 29 Oct 2026

Its shares trade under the ticker GENX. It has been listed since 23 May 2006. In the fiscal year to 31 December 2007, it reported revenue of $3.2m and net income of $342,549. At that date it held total assets of $8.6m and shareholders' equity of $4.7m.

Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft, which is considered as a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2006-05-23. Genex was a start-up, Internet-based fulfillment company with offices in Vancouver, British Columbia, Canada. On June 8, 2004, Genex entered into a share purchase agreement with Tianjin Zhongjin Biology Development Co., Ltd. (Zhongjin). On June 17, 2004, the stock purchase made pursuant to the share purchase agreement was consummated and Zhongjin became a wholly owned subsidiary of Genex. Zhongjin engages in the business of producing and distributing Reconstituted Bone Xenograft (RBX), which is considered a medical device that accelerates bone healing. Zhongjin solely markets its medical devices to hospitals in China. Zhongjin distributes its medical devices to more than 500 hospitals in 30 provinces throughout China. Zhongjin also markets its medical devices to medical device customers in China that are not hospitals.

Figures and description from our data supplier, not checked against the company's own report.

More about Genex Pharmaceutical →

We have not reported on Genex Pharmaceutical yet.

Leaves out fees, taxes and financing.

Chart

TradingView

Close and company data

Our data supplier

News

Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.